Kyoto, Japan

Masafumi Ihara

USPTO Granted Patents = 2 

Average Co-Inventor Count = 4.4

ph-index = 1


Company Filing History:


Years Active: 2018

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Inventor Masafumi Ihara

Introduction

Masafumi Ihara, an accomplished inventor based in Kyoto, Japan, has made significant contributions to the field of radiopharmaceuticals through his innovative work. With a total of two patents to his name, his inventions showcase a deep understanding of chemical compounds and their applications in medicine.

Latest Patents

Ihara's most recent patents include:

1. Radioactive iodine labeled pyrido[1,2-a]benzoimidazole derivative compound - This invention relates to a radioactive iodine-labeled pyrido[1,2-a]benzimidazole derivative compound represented by a specific general formula or a salt thereof, and includes a radiopharmaceutical comprising the same.

2. Radioactive halogen-labeled pyrido [1,2-A] benzimidazole derivative compound - This patent involves a radioactive halogen-labeled pyrido[1,2-a]benzimidazole derivative compound that is depicted by a specific general formula or a salt thereof, as well as a radiopharmaceutical that incorporates this compound.

Career Highlights

Throughout his career, Masafumi Ihara has collaborated with prestigious institutions, notably Kyoto University, where he contributed to various research projects focused on innovative medical technologies. Hiara's work at Nihon Medi-Physics Company Limited has also linked him to advancements in radiopharmacy and the development of diagnostic imaging agents.

Collaborations

Ihara's innovative journey has been enriched through collaboration with notable coworkers, such as Hideo Saji and Masahiro Ono. Their collective expertise has contributed to the success of numerous research initiatives and patent applications in the field.

Conclusion

Masafumi Ihara stands out as a pivotal figure in the realm of pharmaceutical innovation. His patents underscore his commitment to advancing medical science and improving patient outcomes through innovative research and collaboration. As he continues to explore new frontiers in radiopharmaceuticals, his work promises to leave a lasting impact on the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…